It was also demonstrated that cotreatment with vismodegib, a hedgehog pathway antagonist, could sensitize MM cells to carfilzomib, potentially reversing ABCB1-mediated drug resistance [50]. This evidence concerns the gene ABCB1 and Miyoshi myopathy.